Becker's Healthcare July 9, 2024
CAR-T therapy is becoming a more frequent treatment for Medicare patients with diffuse large B-cell lymphoma, but changes in CAR-T treatments that push it as an earlier line of therapy may change where patients receive the therapy — and ultimately, its cost.
In a study published June 25 in Advances in Therapy, researchers concluded it costs significantly more for patients to be treated with CAR-T therapy in the hospital setting compared to outside of it.
Researchers from Kite Pharma and ADVI Health analyzed 391 Medicare claims from patients who received CAR-T therapy between 2021 and 2022 and evaluated the costs and outcomes of patients treated in hospital versus outpatient care.
“Since the FDA’s approval of the first CAR-T product,...
Today's Sponsors
Today's Sponsor